You are here


MBcure is a biopharmaceutical company aiming to develop bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company’s mission is to  develop specific phage cocktails for directed microbiome modulation. The phage drug will carry out targeted suppression of disease-associated gut bacteria demonstrated to cause or exacerbate disease. Platform establishment will benefit from the advanced infrastructural capabilities in the laboratories of the company’s scientific founders (Prof. Rotem Soreq and Prof. Eran Elinav) at the Weizmann Institute of Science, which include high-throughput phage discovery, sequencing and analysis capabilities as well as a ‘germ-free’ mouse facility for generation of controlled microbiome-dependent disease models.